Anti-phospho-JAK2 (Tyr1007/1008)

Species Reactivity	Key Applications	Host	Format	Antibody Type
H, M, R	WB	Rb	Purified	Polyclonal Antibody

Species Reactivity

Key Applications

Host

Format

Antibody Type

H, M, R

Purified

Polyclonal Antibody

Description
Catalogue Number	07-606
Replaces	04-1098
Brand Family	Upstate
Trade Name	Upstate
Description	Anti-phospho-JAK2 (Tyr1007/1008) Antibody
Alternate Names	Janus kinase 2 Janus kinase 2 (a protein tyrosine kinase) tyrosine-protein kinase JAK2
Background Information	JAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor. Among a variety of sites, Tyrosines 1007 and 1008 are sites of trans- or autophosphorylation in vivo and in in vitro kinase reactions.

Description

Catalogue Number

07-606

Replaces

04-1098

Brand Family

Upstate

Trade Name

Upstate

Description

Anti-phospho-JAK2 (Tyr1007/1008) Antibody

Alternate Names

Janus kinase 2
Janus kinase 2 (a protein tyrosine kinase)
tyrosine-protein kinase JAK2

Background Information

JAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor. Among a variety of sites, Tyrosines 1007 and 1008 are sites of trans- or autophosphorylation in vivo and in in vitro kinase reactions.

Product Information
Format	Purified
Control	Human ovarian cancer cells, GM-CSF-treated TF-1 cells.
Presentation	Purified rabbit IgG in buffer containing 0.1M Tris-Glycine, 0.15M NaCl, 0.05% Sodium Azide, pH7.4.

Product Information

Format

Purified

Control

Human ovarian cancer cells, GM-CSF-treated TF-1 cells.

Presentation

Purified rabbit IgG in buffer containing 0.1M Tris-Glycine, 0.15M NaCl, 0.05% Sodium Azide, pH7.4.

Applications
Application	Anti-phospho-JAK2 (Tyr1007/1008) Antibody detects level of phospho-JAK2 (Tyr1007/1008) & has been published & validated for use in WB.
Key Applications	Western Blotting

Applications

Application

Anti-phospho-JAK2 (Tyr1007/1008) Antibody detects level of phospho-JAK2 (Tyr1007/1008) & has been published & validated for use in WB.

Key Applications

Western Blotting

Biological Information
Immunogen	KLH-conjugated, synthetic peptide corresponding to amino acids surrounding phosphotyrosines 1007 and 1008 of human JAK2.
Epitope	Tyr1007/1008
Concentration	Please refer to the Certificate of Analysis for the lot-specific concentration.
Host	Rabbit
Specificity	Recognizes phosphorylated JAK2, Mr 130 kDa.
Isotype	IgG
Species Reactivity	Human Mouse Rat
Species Reactivity Note	Human and mouse. Predicted to cross-react with rat based on sequence homology.
Antibody Type	Polyclonal Antibody
Entrez Gene Number	NP_004963
Entrez Gene Summary	This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis.
Gene Symbol	JAK2 OTTHUMP00000043260 JAK-2
Modifications	Phosphorylation
Purification Method	Protein A Purfied
UniProt Number	O60674
UniProt Summary	FUNCTION: SwissProt: O60674 # Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction. SIZE: 1132 amino acids; 130674 Da SUBUNIT: Interacts with SIRPA (By similarity). Interacts with IL23R, SKB1 and STAM2. SUBCELLULAR LOCATION: Intracytoplasmic membrane; Peripheral membrane protein (By similarity). Note=Wholly intracellular, possibly membrane associated (By similarity). TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph node. DOMAIN: SwissProt: O60674 Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1. DISEASE: SwissProt: O60674 # Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6. & Defects in JAK2 are a cause of susceptibility to Budd- Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites. & Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients. & Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications. & Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. & Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily. & Contains 1 FERM domain. & Contains 1 protein kinase domain. & Contains 1 SH2 domain.
Molecular Weight	130 kDa

Biological Information

Immunogen

KLH-conjugated, synthetic peptide corresponding to amino acids surrounding phosphotyrosines 1007 and 1008 of human JAK2.

Epitope

Tyr1007/1008

Concentration

Please refer to the Certificate of Analysis for the lot-specific concentration.

Host

Rabbit

Specificity

Recognizes phosphorylated JAK2, Mr 130 kDa.

Isotype

IgG

Species Reactivity

Human
Mouse
Rat

Species Reactivity Note

Human and mouse. Predicted to cross-react with rat based on sequence homology.

Antibody Type

Polyclonal Antibody

Entrez Gene Number

NP_004963

Entrez Gene Summary

This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis.

Gene Symbol

JAK2
OTTHUMP00000043260
JAK-2

Modifications

Phosphorylation

Purification Method

Protein A Purfied

UniProt Number

O60674

UniProt Summary

FUNCTION: SwissProt: O60674 # Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.
SIZE: 1132 amino acids; 130674 Da
SUBUNIT: Interacts with SIRPA (By similarity). Interacts with IL23R, SKB1 and STAM2.
SUBCELLULAR LOCATION: Intracytoplasmic membrane; Peripheral membrane protein (By similarity). Note=Wholly intracellular, possibly membrane associated (By similarity).
TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph node.
DOMAIN: SwissProt: O60674 Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.
DISEASE: SwissProt: O60674 # Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6. & Defects in JAK2 are a cause of susceptibility to Budd- Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites. & Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients. & Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications. & Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. & Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily. & Contains 1 FERM domain. & Contains 1 protein kinase domain. & Contains 1 SH2 domain.

Molecular Weight

130 kDa

Product Usage Statements
Quality Assurance	Routinely evaluated by Western Blot on Pervanadate treated L6 lysates. Western Blot Analysis: 1:500 dilution of this lot detected PHOS-JAK2 (TYR1007/1008) on 10 ug of Pervanadate treated L6 lysates.
Usage Statement	Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Product Usage Statements

Quality Assurance

Routinely evaluated by Western Blot on Pervanadate treated L6 lysates.

Western Blot Analysis:
1:500 dilution of this lot detected PHOS-JAK2 (TYR1007/1008) on 10 ug of Pervanadate treated L6 lysates.

Usage Statement

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage and Shipping Information
Storage Conditions	Stable for 1 year at 2-8°C from date of receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Storage and Shipping Information

Storage Conditions

Stable for 1 year at 2-8°C from date of receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Packaging Information
Material Size	200 µg

Packaging Information

Material Size

200 µg

实验耗材

分子生物学试剂

蛋白与免疫学

生化试剂

细胞及检测试剂

色谱及层析

仪器设备

实验服务

办公用品

Anti-phospho-JAK2 (Tyr1007/1008)

浏览了该商品的用户最终购买

浏览了该商品的用户还浏览了

特卖

重要规格表

我要咨询